TLR3 and breast carcinoma: A targeted, specifically engineered exosome containing Hylton alcohol (a toll-like receptor 3 [TLR3] activator) and the immunogenic cell death-inducer human neutrophil elastase (ELANE) has been developed and optimized to form an in situ DC vaccine for breast cancer treatment, enhancing antitumor immunity against breast cancer (56).